| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1365-2559.2011.04116.X |
| P698 | PubMed publication ID | 22260502 |
| P50 | author | Jeremy A. Squire | Q39802515 |
| P2093 | author name string | Maisa Yoshimoto | |
| Kanishka Sircar | |||
| Tarek A Bismar | |||
| Shuhong Liu | |||
| Qiuli Duan | |||
| P2860 | cites work | PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer | Q42473567 |
| Is PTEN loss associated with clinical outcome measures in human prostate cancer? | Q43249619 | ||
| The assessment of PTEN tumor suppressor gene in combination with Gleason scoring and serum PSA to evaluate progression of prostate carcinoma. | Q45876896 | ||
| TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort | Q46231066 | ||
| PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer | Q47919199 | ||
| TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. | Q54561352 | ||
| Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. | Q54566910 | ||
| Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer | Q57693470 | ||
| TMPRSS2-ERG Fusion Prostate Cancer: An Early Molecular Event Associated With Invasion | Q57693484 | ||
| Current Thoughts on the Role of the Androgen Receptor and Prostate Cancer Progression | Q57693532 | ||
| Detection ofERGgene rearrangements andPTENdeletions in unsuspected prostate cancer of the transition zone | Q57790351 | ||
| Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome | Q57790493 | ||
| The role of SPINK1 in ETS rearrangement-negative prostate cancers | Q24647020 | ||
| Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer | Q24650647 | ||
| FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. | Q27851411 | ||
| Essential role for nuclear PTEN in maintaining chromosomal integrity | Q28513781 | ||
| Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis | Q33266259 | ||
| Delineation of TMPRSS2-ERG splice variants in prostate cancer | Q33357287 | ||
| Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer | Q33359279 | ||
| Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer | Q33723651 | ||
| Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor | Q34595342 | ||
| Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues | Q34651198 | ||
| Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. | Q34973214 | ||
| Androgen receptor involvement in the progression of prostate cancer | Q35147116 | ||
| Regulation of androgen receptor levels: implications for prostate cancer progression and therapy | Q36110677 | ||
| FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue | Q36462723 | ||
| Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer | Q36610777 | ||
| Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. | Q36681101 | ||
| Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer | Q37107560 | ||
| Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma | Q37383449 | ||
| Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression | Q37383459 | ||
| EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer | Q37408809 | ||
| The role of androgen receptor mutations in prostate cancer progression. | Q37590123 | ||
| Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate | Q39506775 | ||
| Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer | Q39787898 | ||
| TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. | Q39976204 | ||
| Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer | Q40236516 | ||
| Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias | Q40293372 | ||
| Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers | Q40685677 | ||
| Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis | Q41778982 | ||
| Predictive value of PTEN and AR coexpression of sustained responsiveness to hormonal therapy in prostate cancer--a pilot study. | Q42072658 | ||
| TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy | Q42145160 | ||
| P433 | issue | 4 | |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 645-652 | |
| P577 | publication date | 2012-01-19 | |
| P1433 | published in | Histopathology | Q1524040 |
| P1476 | title | Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer | |
| P478 | volume | 60 |
| Q39457666 | A high-density tissue microarray from patients with clinically localized prostate cancer reveals ERG and TATI exclusivity in tumor cells. |
| Q38833458 | Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH. |
| Q57022565 | Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer |
| Q38052382 | Caspase control: protagonists of cancer cell apoptosis |
| Q49818398 | Clinical implications of PTEN loss in prostate cancer |
| Q42184220 | Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer |
| Q38614981 | Cysteine- rich secretory protein 3 (CRISP3), ERG and PTEN define a molecular subtype of prostate cancer with implication to patients' prognosis |
| Q38774228 | DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer |
| Q38681610 | ERG expression in prostate cancer: biological relevance and clinical implication |
| Q50927287 | ERG protein expression and gene rearrangements are present at lower rates in metastatic and locally advanced castration-resistant prostate cancer compared to localized disease. |
| Q34205227 | Evidence for molecular differences in prostate cancer between African American and Caucasian men |
| Q38142173 | Genomic Rearrangements of PTEN in Prostate Cancer |
| Q27022288 | Interplay between genomic alterations and androgen receptor signaling during prostate cancer development and progression |
| Q34365632 | Molecular pathways and targets in prostate cancer |
| Q36800086 | Molecular profiling of ETS and non-ETS aberrations in prostate cancer patients from northern India |
| Q53638595 | Mutation detection in formalin-fixed prostate cancer biopsies taken at the time of diagnosis using next-generation DNA sequencing. |
| Q39401816 | PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer |
| Q41907553 | PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas |
| Q42371556 | PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort |
| Q51395627 | SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion. |
| Q53644292 | SPINK1 expression in relation to PTEN and ERG in matched primary and lymph node metastatic prostate cancer: Implications for biomarker development. |
| Q48030483 | SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence |
| Q34203149 | SPINK1 protein expression and prostate cancer progression |
| Q39016331 | Serine protease inhibitor Kazal type 1 promotes epithelial-mesenchymal transition through EGFR signaling pathway in prostate cancer |
| Q42782654 | The prognostic significance of combined ERG and androgen receptor expression in patients with prostate cancer managed by androgen deprivation therapy |
| Q37709925 | The role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy |
| Q38980564 | Tumor-derived CXCL8 signaling augments stroma-derived CCL2-promoted proliferation and CXCL12-mediated invasion of PTEN-deficient prostate cancer cells. |
Search more.